Effect Of A Locally Delivered Probiotic Sacchraomyces Boulardii In The Management Of Chronic Periodontitis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03516370 |
|
Recruitment Status :
Completed
First Posted : May 4, 2018
Last Update Posted : May 11, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Periodontitis | Drug: Saccharomyces Boulardii 250 MG | Phase 1 Phase 2 |
1. AIM: To determine effectiveness of saccharomyces boulardii as an adjuvant to scaling and root planing in the treatment of chronic periodontitis 2. OBJECTIVES:
- To evaluate the efficacy of locally delivered saccharomyces boulardii on clinical and microbiological parameters in the treatment of chronic periodontitis.
- To compare the result of scaling and root planning alone and scaling and root planing with locally delivered saccharomyces boulardii in patients with chronic periodontitis.
MATERIALS AND METHODS:- A split mouth, single blind, randomized placebo controlled, clinical & microbiologic study was carried out in 31 patients at the department of Periodontology. Based on power of study i.e 95% and with alpha (α )of 0.05 the sample size finalized was 31. Prior approval for the study was obtained from the Local Ethical Committee. Two interdental suprabony pockets with 5-8mm pocket depth in two different quadrants were chosen as the test site (TS) and control sites (CS).
CONSENT After the study was explained, including the benefits, risks, and alternative treatments, the patients signed an informed consent form indicating their agreement to participate in the study, and each patient was assigned a patient number in ascending order to maintain the masking of evaluators. Eg. First patient was given a number D1, Second D2, and so on.
GROUPS This was a Phase 2 clinical trial with an Interventional model of parallel assignment with two arms. Hence, after screening through inclusion and exclusion criteria in single patient two sites were selected in contralateral quadrants through randomization. 31sites were included in test site and 31 sites were included in control site.
Test Site (TS):- SRP was followed by placement of Lyophilized S boulardii in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula. Periodontal pack was given in delivered area to maintain the mixture into the pocket and patients were advised not to brush in that area. A stent was prepared and probing pocket depth was measured before and after the treatment. The stent enabled the periodontal probe to reach the same position before and after the treatment, to avoid error or bias during treatment.
Control Site (CS):- Control site received placebo i.e distilled water after scaling and root planning.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 31 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Single (Participant) |
| Masking Description: | patients were masked they didnt know which mixture they recived during treatment ensuring single blind study |
| Primary Purpose: | Treatment |
| Official Title: | Effect Of A Locally Delivered Probiotic Sacchraomyces Boulardii As An Adjunct To Scaling And Root Planing In The Management Of Chronic Periodontitis: A Randomized, Split Mouth, Single Blind, Clinico-Microbiological Study |
| Actual Study Start Date : | November 20, 2017 |
| Actual Primary Completion Date : | March 26, 2018 |
| Actual Study Completion Date : | March 26, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: study group
Scaling and root planning was followed by placement of Lyophilized Saccharomyces Boulardii 250 MG in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula.
|
Drug: Saccharomyces Boulardii 250 MG
all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
Other Name: scaling and root planning |
|
Placebo Comparator: control group
Control site received placebo i.e distilled water as a mixture after scaling and root planning.
|
Drug: Saccharomyces Boulardii 250 MG
all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
Other Name: scaling and root planning |
- pocket depth reduction [ Time Frame: 1 month ]after subgingival delivery of lyophilized s. boulardi mixture the pocket depth shiuld recived after 1 month
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 35 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Systemically healthy subject.
- Presence of minimum 16 teeth.
- Patient with generalized moderate to severe chronic periodontitis.
- Probing depth (PD) 5-8mm.
- Clinical Attachment Level > 4mm
Exclusion Criteria:
- Tobacco in any form and alcoholics.
- Pregnant and lactating mother.
- Patients with history of systemic ailments, patients under ant-inflammatory/antibiotic/antifungal/probiotic/prebiotic 6 months prior to recruitment for study.
- Subjects who had received periodontal treatment within the previous 6 months.
- Aggressive periodontitis.
- Patients with confirmed or suspected intolerance to S,boulardii derivatives will be excluded from the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03516370
| India | |
| Dental | |
| Kolhapur, Maharashtra, India, 416113 | |
| Study Chair: | Dilip Khambete, MDS | tatayasaheb kore dental college and hospital new pargaon |
| Responsible Party: | Dr.Kshitij .K. Karmkar, Principle investigator, Tatyasaheb Kore Dental College |
| ClinicalTrials.gov Identifier: | NCT03516370 |
| Other Study ID Numbers: |
9403303401 |
| First Posted: | May 4, 2018 Key Record Dates |
| Last Update Posted: | May 11, 2018 |
| Last Verified: | May 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
chronic periodontitis Sacchraomyces boulardii probiotics |
|
Periodontitis Chronic Periodontitis Periodontal Diseases Mouth Diseases Stomatognathic Diseases |

